TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect TriSalus Life Sciences to post earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Stock Up 0.5 %

Shares of TLSI stock opened at $5.67 on Tuesday. The firm has a market capitalization of $172.90 million, a price-to-earnings ratio of -2.28 and a beta of 0.48. The stock has a fifty day moving average of $5.34 and a 200 day moving average of $4.72. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In other news, CEO Mary T. Szela bought 4,826 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were purchased at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the purchase, the chief executive officer now owns 429,503 shares in the company, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Emmett Young purchased 6,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Wednesday, February 5th. The shares were purchased at an average cost of $5.65 per share, with a total value of $33,900.00. Following the transaction, the chief financial officer now directly owns 30,000 shares of the company’s stock, valued at $169,500. This represents a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 54,856 shares of company stock worth $294,608. 32.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Roth Mkm reaffirmed a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.56.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.